Clinical trial registry record

Multicenter Clinical Study of the SING-IMT in Patients with Late-stage AMD

A registered study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Recruiting.
Evidence
Registered phase not reported study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated December 3, 2024.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT05438732
Last registry update
December 3, 2024
Status
Recruiting
Phase
Phase not reported
Sponsor
VisionCare, Inc.
Enrollment
125
Countries
United States
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase not reported
Study design
NA · SINGLE GROUP · OTHER · NONE
Evidence population
Human clinical study registration
Participants
125
Population
ALL · 65 Years
Duration
2022-06-16 to 2025-12-01
Intervention
smaller incision, new generation implantable miniature telescope (SING-IMT)
Comparator
Not reported
Outcomes measured
Primary Effectiveness Outcome — Approximately 12-months post-operatively (330-420 days); Primary Safety Outcome — Approximately 12-months post-operatively (330-420 days); Best-corrected distance visual acuity (BCDVA) — Approximately 12-months post-operatively (330-420 days); Best-corrected near visual acuity (BCNVA) — Approximately 12-months post-operatively (330-420 days); Anterior Chamber Depth — Approximately 12-months post-operatively (330-420 days); IMT position — Approximately 12-months post-operatively (330-420 days); Adverse Events — Approximately 12-months post-operatively (330-420 days); Posterior Capsule Opacification — Approximately 12-months post-operatively (330-420 days)
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase not reportedA trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 100%Abstract contains controlled term: age-related macular degeneration. Source terminology contains: age-related macular degeneration. Abstract supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.

Automated source check 100% · update recency 65%. These figures help sort records; they are not medical ratings.

vision aging
Open primary sourceExport JSON